Medicus Pharma (MDCX) Amortization of Deferred Charges (2024 - 2025)
Medicus Pharma (MDCX) reported Amortization of Deferred Charges of $339381.0 for Q4 2025, up 1152.41% on a YoY basis from $27098.2 in Q4 2024, and up 278.44% quarter-over-quarter from $89680.0 in Q3 2025.
Medicus Pharma (MDCX) Amortization of Deferred Charges (2024 - 2025) Analysis & Trends
Medicus Pharma has reported Amortization of Deferred Charges for 2 years, with the latest figure at $339381.0 in Q4 2025.
- For the quarter ending Q4 2025, Amortization of Deferred Charges rose 1152.41% year-over-year to $339381.0; the trailing twelve-month figure through Dec 2025 stood at $405796.0 (changed N/A YoY), and the FY2025 full-year result was $429061.0, up 479.77% from the prior year.
- Amortization of Deferred Charges for Q4 2025 stood at $339381.0, up from $89680.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $339381.0 in Q4 2025, with the low at -$32248.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Medicus Pharma | 7.87 Mn | 7.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 339,381.00 |
| Dec 31, 2025 | 339,381.00 |
| Sep 30, 2025 | 89,680.00 |
| Sep 30, 2025 | 89,680.00 |
| Dec 31, 2024 | -32,248.00 |
| Dec 31, 2024 | -32,248.00 |
| Sep 30, 2024 | 8,983.00 |
| Sep 30, 2024 | 8,983.00 |